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Tiivistelmä  - Referat – Abstract  
In atherosclerosis, cholesterol accumulates in cholesterol-loaded macrophages (foam cells) forming cholesterol 
plaques in the arterial intima. Reverse cholesterol transport (RCT) is a mechanism in which HDL and its major 
structural protein apolipoprotein-A-1 (apoA-1) remove cholesterol from the foam cells and take it to the liver for its 
final excretion from the body in the faeces. An impaired removal of cholesterol from the foam cells is a potential 
contributor to a reduced RCT, which is related to a higher incidence of coronary heart disease.  
 
Chymase, a neutral protease of mast cells (MCs), is widely distributed in the connective tissue of most vertebrates 
and able to degrade apoA-1. After the degradation, HDL-particles are unable to interact with the ABCA-1 
transporter protein on the surface of macrophages, which mediates efflux of cholesterol from the macrophage foam 
cells to HDL particles. It has been shown that chymase derived from rat peritoneal MCs is able to degrade apoA-1 
even in the presence of blood plasma which contains natural inhibitors for chymase (α-2-macroglobulin and α-1-
antichymotrypsin).  
 
In the present study we wanted to find out if mouse mast cell protease 4 (mMCP-4) isolated from peritoneal mast 
cells is able to maintain its enzymatic activity even in the presence of mouse serum and intraperitoneal fluid. A 
small molecular weight compound (S-2586) was used as a substrate. In the in vitro experiments a sonicated MC 
preparation that contains active chymase was used and the activity of chymase was measured in the presence of 
varying concentrations of plasma and intraperitoneal fluid. In the in vivo experiments we evaluate whether mast 
cell-dependent proteolysis of HDL particles does occur, and whether such modification inhibits their efficiency in 
inducing cellular cholesterol efflux in vitro.  
 
We found that both serum and intraperitoneal fluid inhibited chymase activity, serum to a higher extent. Systemic 
activation of MCs in mast cell-competent mice, but not in mast cell-deficient mice, in vivo led to a decreased 
ability of plasma and intraperitoneal fluid to act as cholesterol acceptors from cultured cholesterol-loaded 
macrophages. Local activation of peritoneal mast cells also blocked the cholesterol efflux-inducing effect of 
intraperitoneally injected human apoA-1. 
 
This work was performed at the Wihuri Research Institute. Licenses for animal work were approved by the Finnish 
Laboratory Animal Experiment Committee (Suomen eläinkoelautakunta, ELLA). Laboratory animals (female 
NMRI mice) were from the Viikki Laboratory Animal Centre of the University of Helsinki and the mast cell 
deficient strain of mice W-sash c-kit mutant KitW-sh/W-sh were from the Jackson Laboratory (BarHarbor, Maine).  
The work was supervised by the director of the Research Institute Petri Kovanen MD PhD and Miriam Lee-
Rueckert PhD. Laboratory assistance was perceived from the technicians of the Wihuri Research Institute. 
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Tiivistelmä - Referat – Abstract  
Valtimonkovettumistaudissa kolesteroli kertyy valtimon intiman makrofaagisoluihin, muodostaen kolesteroli 
plakkeja. Kolesterolin täyttämiä makrofaagi sluja kutsutaan vaahtosoluiksi. Kolesterolin käänteiskuljetuksessa 
HDL (High density lipoprotein) ja sen merkittävä rakenteellinen proteiini apolipoproteiiniA-1 (apoA1) 
poistavat kolesterolia vaahtosoluista. Ongelmat kolesterolin poistossa vaahtosolusta, johtavat vähentyneeseen 
kolesterolin käänteiskuljetukseen, mikä taas osaltaan voi johtaa kohonneeseen riskiin sairastua 
valtimonkovettumistautiin. 
     
Syöttösolut ovat tulehdussoluja ja niitä voidaan löytää useimpien selkärankaisten sidekudoksista, mutta niiden 
rakenteessa ja toiminnassa on huomattavia eroja. Syöttösolun kymaasi-entsyymillä on kyky pilkkoa apoA-1:ä. 
Lipoproteiinin pilkkouduttua, HDL partikkeli ei enää pysty kiinnittymään ABCA-1 kuljettajaproteiiniin 
makrofaagin pinnalla. Jos kiinnittymistä ei tapahdu, kolesterolin siirtyminen vaahtosolusta HDL-partikkeliin 
estyy.  Aikaisemmissa tutkimuksissa on havaittu, että HDL-partikkelien lisääminen viljelynesteeseen, jossa on 
rotan peritoenaaliontelosta eristettyjä aktivoituja syöttösoluja, johtaa nopeasti hiukkasten proteolyyttiseen 
hajoamiseen. Tämä ilmiö on havaittavissa myös silloin, kun viljelynesteessä on veriplasmaa, joka sisältää 
kymaasin fysiologisia inhibiittoreita α-2-mackroglobuliinia ja α-1-antikymotrypsiiniä.  
 
Kyseisessä tutkimuksessa halusimme selvittää, kykeneekö hiiren peritoenaaliontelon syöttösolujen kymaasin 
kaltaisen entsyymi (mouse mast cell protease 4 eli MCP 4) säilyttämään entsymaattisen aktiviteettinsa myös 
silloin, kun syöttösoluista eristettyjä granuloita pidetään seerumia tai peritoneaalinestettä sisältävässä 
viljelynesteessä. Substraattina käytettiin pienikokoista synteettistä molekyyliä (S-2586). In vitro kokeissa 
hiirten vatsaontelosta eristettyjen syöttösolujen granulat vapautetaan viljelynesteeseen ja niiden aktiivisuus 
määritetään vaihtelevissa plasma- tai peritoneaalineste-konsentraatioissa. In vivo kokeissa tarkasteltiin, 
tapahtuuko syöttösoluista johtuvaa  HDL-partikkelien hajoamista, kun hiiren syöttösoluja aktivoidaan, ja 
johtaako tämä HDL-partikkelien muuntuminen niiden heikentyneeseen kykyyn toimia kolesterolin 
vastaanottajana in vitro.   
 
Kokeissa totesimme, että hiiren seerumi ja peritoneaalinesteessä on tekijöitä, jotka estevät kymaasi-entsyymin 
toimintaa. In vivo kokeissa todistimme, että hiiren syöttösolujen aktivaatio johtaa alentuneeseen kolesterolin 
ulosvirtaukseen vaahtosoluista tavallisilla, mutta ei syttösolu puutteisilla hiirillä, kun kolesterolin 
vastaanottajina toimivat syöttösoluaktivoitujen hiirien seerumi ja peritoneaalineste. Syöttösolujen paikallinen 
aktivaatio vähensi myös hiiren vatsaonteloon injisoidun ihmisen apoA-1:n kykyä toimia kolesterolin 
ulosvirtauksen indusoijana.  
 
Kaikki artikkelia varten suoritetut in vivo, in vitro ja laboratoriokokeet suoritettiin Wihurin tutkimuslaitoksella.  
Koe-eläminä käytetyt NMRI naaras hiiret tilattiin Helsingin yliopiston Viikin koe-eläin yksiköstä ja mast solu 
puutteiset W-sash c-kit mutant KitW-sh/W-sh hiiret Jackson Laboratoriosta (Bar Harbor, Maine). Luvat 
eläinkokeisiin haettiin Suomen eläinkoelautakunnalta (ELLA). Työnjohtajina toimivat Wihurin 
tutkimuslaitoksen johtaja professori Petri Kovanen sekä tutkimuslaitoksen tutkija, Havannan yliopiston 
professori Miriam Lee. Laboratoriotutkimuksissa avustivat ja ohjasivat tutkimuslaitoksen teknikot. 
Avainsanat – Nyckelord – Keywords  
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1.Abstract. Objective and Design: Atherosclerosis is one of the most serious threats 
to life and health in the aging populations in western world. Risk factors such as 
smoking habits, blood pressure, serum total cholesterol, sex and weight contribute to 
the incidence of coronary heart disease. In the early onset of atherosclerosis 
cholesterol accumulates in the macrophages of arterial intima. High density 
lipoproteins (HDL) remove cholesterol from the cholesterol-loaded macrophages 
(foam cells) in the intima. This constitutes the first step of reverse cholesterol 
transport (RCT) that is the process by which cholesterol in peripheral cells is 
transferred to the liver to its final excretion in the faeces. An impaired removal of 
cholesterol from the foam cell is a potential contributor to a reduced RCT, which is 
related to a high incidence of coronary heart disease.  
Activated mast cells degranulate releasing their cytoplasmic granules. Granules 
contain a neutral protease, chymase that degrades a major structural protein of HDL, 
apolipoproteinA-I (apoA-I). It has been shown that shortly after adding HDL particles 
to culture medium containing activated mast cells isolated from the rat peritoneal 
cavity (rMCs), there is proteolytic degradation of HDL particles. Proteolyzed HDL 
particles are unable to remove cholesterol from foam cells in vitro. After degradation, 
HDL particles are unable to interact with the ABCA-1 transporter protein on the 
surface of macrophages, which mediates the efflux of cellular cholesterol to HDL 
particles. It is to be noted that chymase from rat peritoneal MCs is able to degrade 
apoA-I even in the presence of blood plasma which contains natural inhibitors for 
chymase (α-2-macroglobulin and α-1-antichymotrypsine). In the rat MC granules, 
chymase is attached to heparin proteoglycan, which gives it resistance by hindering 
the attachment of inhibitors to the active part of the enzyme. 
Animal models in atherosclerosis research are essentially based on genetically 
manipulated mice. Therefore it is pivotal to study the mechanism operating in mice. It 
is not known whether peritoneal mouse mast cell (mMC) heparin can also prevent the 
action of plasma protease inhibitors on chymase in the granules.  
Our first challenge was to find out if the chymase-like mouse mast cell protease 4 
(mMCP-4) contained in mouse peritoneal MCs was able to maintain its enzymatic 
activity in the presence of serum and peritoneal fluid. As a substrate for chymase we 
used a small molecular weight agent S-2586. In the in vitro experiments mouse 
peritoneal MCs were sonicated and the activity of active chymase was measured in 
increasing concentrations of serum and intraperitoneal fluid.  
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In this report we will also include the results of a study comparing acute, subacute and 
chronic activation of mast cells in vivo. In the in vivo experiments we evaluate 
whether acute, subacute and chronic activation (systemic or local activation 
respectively), of mast cells in vivo leads to a decreased ability of HDL particles 
present in mouse plasma and intraperitoneal fluid to act as cholesterol acceptors from 
macrophage foam cells in vitro. We also evaluate whether local activation of 
peritoneal mast cells leads to a decreased ability of intraperitoneally injected human 
apoA-1 to promote cholesterol efflux in vitro. 
 
 
Key words: ABCA1, atherosclerosis, chymase, cholesterol efflux, foam cells, 
macrophages, mouse peritoneal mast cells, mouse mast cell protease-4, high density 
lipoproteins, proteolysis    
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2. Introduction. Mast cells are bone marrow-derived cells best known for their 
harmful effects on hypersensitivity reactions. Mast cell precursors circulate in the 
blood and migrate into connective or mucous tissues where they differentiate into 
mature mast cell phenotypes depending on the microenvironment of the tissue [1]. 
During the differentiation, granules containing histamine, heparin and several proteins 
are created in the cytoplasm [2]. Upon activation, mast cells release their granules and 
play a central role in the early stages of inflammatory processes [3]. Apart from their 
role in acute inflammatory reactions mast cells are also involved in several other, 
more chronic inflammatory processes, e.g. wound repair, arthritis, scleroderma, and 
atherosclerosis.  
Mast cells are widely distributed in the connective tissue of most vertebrates and their 
histochemical, biochemical and functional properties can differ substantially 
according to their anatomic location [4].  
Mast cells express high affinity FcεRI receptors on their cell membrane specific for 
IgE antibodies. Other Fc receptors such as FcγRIII specific for IgG are also expressed 
[5]. Immunologic activation of mast cells is initiated when a multivalent antigen with 
its specific IgE antibody is bound to the FcεRI receptor on the cell membrane. Cross 
linkage of the immunoglobulin is needed for the activation. MC activation leads to a 
rapid release of intracellular granules to the environment. MC degranulation can also 
be induced by non-immunologic stimulators e.g. by the exposure to complement 
factors C3a and C5a or by stimulation of neuropeptides (e.g. substrate P) via its high 
affinity receptor FcεRI [6]. IgE cross-linkage may be induced artificially by the use of 
anti-IgE antibodies or antibodies against the IgE receptor. Also a family of polybasic 
molecules is known to simulate exocytosis from mast cells. Members of this family 
include compound 48/80, mastoparan, polymyxin B, and polymers of basic amino 
acids.  
Activated mast cells release their granules to the extracellular environment. The 
granules contain neutral proteases, histamine, growth factors and cytokines. The 
proteases are bound to macromolecular heparin complexes which may serve to 
package the proteases in a configuration that prevents their autolysis either before or 
after exocytosis. Due to their large size, the complexes also prevent wide and rapid 
diffusion of the proteases into uninvolved tissues. Mast cell activation may also be 
followed by the synthesis of chemokines and cytokines. Cytokine and chemokine 
secretion, which occurs hours later, may contribute to chronic inflammation.  
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The neutral proteases of mast cells can be divided into three different classes: 
tryptases, chymases and carboxypeptidase A [7].  Chymases are chymotrypsin-like 
serine proteases and are further divided into α-chymases and β-chymases based on 
their structural homologies. α-chymases are present in most mammals, including 
humans whereas β-chymases appear to be rodent specific [8]. 
Mast Cells in a mouse can be divided into two major phenotypes, mucosal mast cells 
(MMC) and connective tissue mast cells (CTMC). Rodents express a number of 
mouse MC proteases (mMCP), namely, various β-chymases designated mMCP1, 
mMCP2 and mMCP4 as well as one α-chymase, mMCP5. The different chymases 
differ significantly regarding to their tissue distribution e.g. mouse chymases are only 
50-76% identical. CTMCs located in various tissues such as skin, tongue and 
peritoneum express mMCP4 and mMCP5. MMCs located in the intestinal tract 
express mMCP1 and mMCP2 [9]. Highly cationic CTMC chymases are stored in tight 
contact with heparin proteoglycans. In contrast, the nearly neutral MMC chymases 
have low heparin affinity and are highly soluble and diffusible upon release. Thus 
physiological properties of chymases vary considerably.  
The exact role of chymase is still unclear, no truly specific substrate is known. Yet 
chymase is involved in many physiological actions. Chymases destroy extracellular 
matrix proteins, activate matrix metalloproteinases, potentiate plasma leakage, 
stimulate sub mucosal gland cell secretion, inactivate inflammatory neuro-peptidases, 
degrade lipoproteins, control complement mediated inflammation, promote 
angiogenesis and generate extra vascular angiotensin II. Chymase is also involved in 
the regulation of proteolysis in the extracellular matrix thus exaggerating the 
destruction of cardiac interstitium and promoting the excessive wound healing 
response in cardiac fibrosis [10-13]. 
Once secreted to the neutral extracellular matrix, chymase becomes active, while in 
the acid environment of the granules, chymase remains inactive. High ionic strength 
also decreases chymase activity. In the extracellular fluid chymase is surrounded by 
both substrates of chymase, such as apoA-I, and by its inhibitors, such as α1-
chymoptrypsin, α2-macroglobulin and α2-antichymotrypsin [14]. Incubation with 
human plasma results in over 80% inhibition of human chymase hydrolytic activity 
for small substrates [15]. It has also been proved that when chymase is bound to the 
granule remnants, it is partially resistant to the inhibitory action of the protease 
inhibitors present in serum and thus able to degrade apoA-I in serum, whereas isolated 
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and purified chymase is very susceptible to protease inhibitors found in serum. 
Chymase bound to glycosaminoglycan chains is more resistant to the high molecular 
weight protease inhibitors present in mammalian plasma than to synthetic or non-
physiological low molecular weight protease inhibitors.     
MCs are found in atherosclerotic plaques in the near vicinity of cholesterol filled foam 
cells in the arterial intima. In normal physiological conditions the RCT facilitates the 
exertion of cholesterol from the body. In the arterial intima, LDL carry cholesterol to 
macrophages (influx), and HDL remove it from the macrophage membrane (efflux) 
by different mechanisms. The various subclasses of HDL play a crucial role in the 
initiation of RCT by mediating the transfer of excess cholesterol from macrophages to 
the liver for excretion. HDL can be found independently or together associated with 
other proteins such as cholesteryl ester transfer protein (CETP) which can amplify 
stability against enzymatic degradation [16]. The primary and most efficient 
cholesterol acceptors seem to be small discoidal lipid-poor pre-β-HDL which in 
certain conditions matures to spherical α-HDL particles. Both pre-β-HDL and α-HDL 
promote the efflux of cholesterol from macrophage foam cells via the ATP binding 
cassette transporters ABCA1 and ABCG1 respectively [17]. Efflux facilitated by the 
ABCA-1 is unidirectional and leads to net removal of cellular cholesterol. HDL 
particles then transport the cholesterol from periphery to liver. Scavenger receptor B1 
(SR-B1) facilitates the cellular uptake of cholesterol from HDL to the liver [18]. The 
final step of RCT is the transport of cholesterol and the bile acids from the liver via 
the bile duct and intestine to faeces.  
In arterial intima activated MCs release their granules to their environment where MC 
proteases are able to degrade their substrates. Various other proteases found in the 
human arterial intima reduce the ability of HDL to induce cellular cholesterol efflux 
in vitro [19,20]. It is believed that chymase is able to degrade apoA-I, the main 
apolipoprotein of HDL, thus impairing the early step of RCT. Any disorder in RCT 
results in reduced excretion of cholesterol from the body. In chronic inflammatory 
process of atherosclerosis RCT may be impaired and in the inflamed arterial wall 
cholesterol accumulates as a consequence of an imbalance between cholesterol influx 
and efflux.  
In this study we have compared the effect of three methods of activating MCs on the 
function of HDL particles as cholesterol acceptors  
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3. Materials and Methods.   
 
3.1. Materials 
Heparin, Albumin from bovine serum (BSA) and mast cell degranulating factor 48/80 
were purchased from Sigma Aldrich. S-2586, chromogenic substrate from 
Chromogenix. Medetomidine: Domitor
®
, medetomidine 1 mg/ml from Orion Pharma. 
Ketamin: Ketaral
®
, ketamin 50 mg/ml from Pfizer. Dulbecco’s Phosphate Buffered 
Saline (DPBS), Dulbecco’s Modified Eagle’s Medium (DMEM) and RPMI-1640 
medium were from Cambrex.  
 
 
3.2. Animals 
Female NMRI mice aged 10-12 weeks were from the Viikki Laboratory Animal 
Centre of the University of Helsinki and the mast cell-deficient strain of mice W-sash 
c-kit mutant KitW-sh/W-sh were purchased from the Jackson Laboratory (Bar Harbor, 
Maine). The mice were housed 5 per cage in community cages with 12-h periods of 
light and dark cycles in controlled temperature and humidity and provided with 
standard chow diet and water ad libitum.  
The licences for the laboratory animal experiment were approved by the Finnish 
Laboratory Animal Experiment Committee (Suomen eläinkoelautakunta, ELLA). 
Licence number ESLH-2007-05892/Ym-23. 
 
 
3.3. Preparation of mast cell suspensions and the release of mast cell granules 
Connective tissue mast cells were isolated from the peritoneal cavities of mice. For 
that, mice were sacrificed in CO2 chamber and death assured by cervical dislocation. 
Ethanol was sprayed over the abdomen and carefully dried with paper. A little piece 
of skin was removed to visualise the peritoneal cavity better. Five ml of Isolation 
buffer (PBS: BSA 2:1 and heparin) were then injected into the peritoneal cavity. The 
abdomen was gently massaged for about 1 min to stimulate the detachment of mast 
cells. The peritoneal cavity was opened with scissors and the fluid collected with 
Pasteur pipette. The fluid from each mouse was collected to a 50 ml centrifuge Falcon 
tube to yield a pool. The fluid obtained was centrifuged at 200 x g for 5 min after 
which the cells were resuspended in a medium of RPMI-1640 containing BSA, 
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penicillin and L-glutamic acid in ratio 1:100 1ml/mouse and placed into Petri dish. 
Macrophages were let to adhere to the plastic surface of the Petri dish for 1 h at 37˚C. 
After the incubation, the medium was collected to recover the non-adherent cells and 
transferred into a new 50-ml centrifugation tube. The dish was washed with PBS and 
the PBS is added to the tube. The fluid was centrifuged at 200 x g for 5 min after 
which the pelleted cells were resuspended in 1 ml of Isolation buffer. The cells were 
counted by staining the cells in 1:1 vol in Moore & James and counting them in 
Bürkers chamber.  After counting the cells they were sedimented at 200 x g, 5 min. 
PBS was added to reach the concentration 1000 MCs/μl. Cell suspension was 
sonicated on ice for 10 sec at a constant duty cycle (Branson sonicator, model 250). 
Cell suspension was then centrifuged twice and washed with PBS.  
Chymase activity was measured by spectrophotometer in a 96-well microtiter plate. 
Absorbance was measured at 405 nm at 30 second intervals for 5 minutes (11 
measurements). One arbitrary unit corresponds to a 0.0001 increase in absorbance at 
405 nm/min under the described conditions of the assay. Each well contained 20μl of 
the peritoneal mast cell extract corresponding 20 000MCs in H2O to reach the final 
volume of 100µl. First corresponding volume of H2O was placed on microtiter well 
followed by the addition of mast cell extract and 20μl of 1.8 mM solutions of 
chromogenic substrate for chymotrypsin-like proteases (S-2586). Immediately after 
the addition of the substrate the changes in absorbance were measured at 405 nm. 
Chymase activity was also measured in the presence of its natural inhibitors found in 
serum and intraperitoneal fluid.  
 
 
3.4. Chymase activity in the presence of natural inhibitors. 
To determine the inhibitory effect of the natural inhibitors of chymase such as α2-
macroglobulin and α-1antichymotrypsine, the activity of chymase was measured in 
the presence of mouse plasma and mouse IP fluid. The activity of chymase was 
determined as described above. Plasma was added to reach the final concentrations 
from 0% to 80%, the number of MCs being 20 000/assay (20µl of MC preparation) in 
100μl of reaction mixture. Blood was obtained by cardiac puncture after sacrificing 
the animals. Intraperitoneal fluid was collected with a pipette from a small incision 
made to the linea alba of the mouse.  
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3.5. Acute activation of mMCs in vivo – systemic anaphylaxis  
Four independent experiments using 60 NMRI and 12 mast cell deficient sash mice 
were performed.  
Mice were given intraperitoneal injections of compound 48/80 to induce systemic 
anaphylaxis and systemic stimulation MCs as previously described [19, 20]. Mice 
were kept under surgical anaesthesia over the trial. As an induction dose mice were 
given subcutaneous injection of 1mg/kg medetomidine + 75mg/kg ketamine of body 
weight. Mice were kept in surgical anaesthesia and anaesthesia was monitored by 
existence of leg flexing reflex. Anaesthesia was maintained with further doses of 
anaesthetics if needed.   
To induce systemic anaphylaxis mice were given intraperitoneal injection of the non 
cytotoxic mast cell degranulator compound 48/80 in a dose 8 mg/kg of body weight. 
Mice matched for weight and sex received corresponding volumes of NaCl 0.9% 
(control group). Mortality was monitored for 30 minutes after induction of 
anaphylactic shock. Control mice were sacrificed at matching death times at a 
separate trial. All survivor mice were sacrificed at 30 minutes after the injection. 
Death was assured with cervical dislocation in all mice.  
IP and blood from the heart of each mouse was obtained post mortem. All the samples 
were stored at -70ºC until analysis. Serum and IP fluid were tested for their function 
as cholesterol acceptors as described below.  
 
 
3.6. Sub acute activation of mCTMCs in vivo 
Mouse peritoneal mast cells were sub acutely activated on a course of one day. The 
activation of the MCs in this case is local. The protocol is modified from previous 
work as previously described [21-24]. Mice (N=10) received five IP injections of 
compound 48/80 within 6 hour time span. The dose employed was 1.5 mg/kg. Control 
mice (N=10) received 0.9% saline instead of compound 48/80 on matched time 
points. Mice received five injections; first three injections were administered at an 
interval of one hour followed by two more injections at an interval of two hours. Mice 
were given analgetics 15 minutes before the first injection of compound 48/80. 
Medetomidine (1 mg/kg) was injected s.c. and the sedative state sustained by three 
lower doses of medetomidine every two hours. The maintenance dose was 70% of the 
induction dose. Five minutes after the last injection of 48/80, the mice were scarified 
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in CO2 chamber and death assured by cervical dislocation. The peritoneal mast cells 
were collected by peritoneal lavage from five mice and i.p. fluid collected from 
peritoneum of five mice. The blood from the heart of each mouse was obtained by 
cardiac punctuation. The samples were stored at -70ºC until analysis. Mice were kept 
in individual cages on the course of the experiment.  
 
 
3.7. Chronic activation of mCTMCs in vivo 
Mouse peritoneal mast cells were chronically activated on a course of five days as 
previously described [22-24]. The activation of the MCs is local.  The mice (N=10) 
received repeated injections of compound 48/80. Compound 48/80, dissolved in PBS 
was given i.p. in the morning and evening, altogether eight times, starting with an 
evening dose. The dose of 48/80 employed was 0.6mg/kg for the first three injections 
and 1.2mg/kg for the last five injections. Control mice (N=10) received an injections 
of 0.9% saline instead of compound 48/80. Six hours after the last morning injection 
on the morning of the day five the mice were scarified in CO2 chamber and death 
assured by cervical dislocation. The peritoneal mast cells were collected by peritoneal 
lavage. The blood from the heart of each mouse was obtained by cardiac punctuation. 
The samples were stored at -70ºC until analysis.  
 
 
3.8. Cholesterol determination  
Cholesterol (CHOD-PAP Roche/Hitachi) is determined from the undiluted mouse 
serum. As cholesterol standards commercial standards from Bioclin Oy are used. 
Absorbance at 490 nm was measured by using a 96-well microtiter plate. Results are 
calculated from the linear absorbance curve. 
 
 
3.9. Proteolytic inactivation of apoA-1 by mouse chymase in vitro 
Human lipid-free apoA-1 (50µg) (kindly provided by Dr. Peter Learch, Swiss Red 
Blood, Bern, Switzerland) was incubated at 37ºC for 3 hours with increasing 
concentrations of the mast cell lysate (chymase activity 20U/µl) in a final volume of 
250µl in 5mM Tris-HCl, pH 7.4, containing 150mM NaCl, 1 mM EDTA (TNE 
buffer). The incubation was stopped by centrifugation at 10 000rpm for 10 min at 4ºC. 
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The degradation of apoA-1 was analyzed by 15% SDS-PAGE and Western blot 
analysis and the ability of chymase treated mixtures to induce cellular cholesterol 
efflux was evaluated as described below. 
 
 
3.10 Proteolytic inactivation of apoA-1 by mouse chymase in vivo 
Mice (5 animals per group) received intraperitoneal injections of C48/80 administered 
in doses 0.5-1.0 mg/kg to induce local activation of mast cells with human apoA-1 (3-
30 mg/kg) in 500µl of NaCl 0.9%. Other groups received equal amounts of only 
apoA-1 or only NaCl 0.9% and acted as control group. After 3 hours mice sacrificed 
and the ability of serum and intraperitoneal fluid to induce cellular cholesterol efflux 
was evaluated in each group as described below. 
 
 
3.11. Cholesterol efflux from macrophage foam cells to serum and IP fluid derived 
from MC stimulated mice 
Macrophages are isolated from the cavities of normal NMRI mice and loaded with 
radioactive acetylated LDL to form foam cells as described by Lindstedt et al 1996. 
Mouse serum and IP fluid are used as cholesterol acceptors. 
 
3.11.1. Isolation of macrophages 
Macrophages were isolated from the peritoneal cavities of mice. For that, mice were 
sacrificed in the CO2 chamber and death assured by cervical dislocation. Ethanol was 
sprayed over the abdomen and carefully dried with paper. A little piece of skin was 
removed to visualise the peritoneal cavity better. Four ml of PBS with BSA 1mg/ml 
was injected into the peritoneal cavity. Before use, the buffer was filtered with 
Millipore 0.20 μm in laminar flow hood to sterilize the fluid. After the IP injection the 
abdomen was gently massaged for about 1 min to stimulate the detachment of cells.  
The peritoneal cavity was opened with scissors and the fluid collected with Pasteur 
pipette. Macrophages were allowed to adhere on plastic Petri dishes for 1-2 hours at 
37 ºC humidified CO2. 
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3.11.2. Loading the macrophages  
The macrophages were washed with PBS w/o Ca and Mg (x3) and 300μl DMEM- 1% 
P/S containing 20% FCS and the mixture of cold and acetylated radioactive acetyl-
LDL (20 µg/ml, 100 000 dpm/well) was added, as described before [26]. 
Macrophages are incubated over night at 37 ºC, 5% CO2. 
 
3.11.3. Cholesterol efflux 
The macrophages were washed as above and 300μl DMEM-1%P/S (without FCS) 
containing mouse serum or IP fluid of varying concentrations as acceptors was added. 
Hirudin 10 UI/ml of media was added to prevent coagulation. Cells were incubated 4h 
at 37 ºC, 5% CO2.  After incubation medium was taken to vials and centrifuged at 200 
x g for 5 minutes. Radioactivity was measured in the media. The macrophages were 
dissolved in 0.2 M NaOH and the radioactivity of the cells was measured from the 
cell extract.  
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4. Results.  
 
4.1. Chymase activity in mouse mast cell lysates  
For our purposes it was pivotal that chymase would act as it would in a physiological 
environment, therefore we employed MC preparations obtained in three different 
conditions and the activity of chymase was measured in the presence of various 
concentrations of mouse serum. MC granules were obtained either by lysis buffer 
(PBS, 0.5% Triton X-100) with or without high sodium chloride concentration (2 M 
NaCl) or by sonication in PBS (Figure 1). Absolute chymase activity in arbitrary 
units (AU) was highest in the preparation where MCs were sonicated and chymase 
suspended in PBS (46 AU ± 3.6). High sodium chloride concentration clearly inhibits 
the activity of chymase (17 AU ± 1.0) and so does lysis buffer (38 AU ± 3.2) but with 
a minor effect. When the values of chymase activities of the three preparations were 
set as 100% and the ability of increasing concentrations of serum to inhibit chymase 
activity was expressed as % inhibition, it appeared that the maximal inhibition 
observed at 50% serum was about 70% both for the preparation obtained using lysis 
buffer without NaCl and the preparation obtained using sonication. Importantly, at 
10% serum concentration, which mimics the serum present in the extra vascular 
compartment, approximately 50% of the activity of chymase remained. Based on 
these results we chose the sonication method for the following studies using PBS 
which produced higher absolute chymase activity and less variation in the results as 
the buffer, and also provided a more physiological ionic strength. 
 
Since the physiological properties of chymases differ so markedly, we wanted to 
measure chymase activity derived from mouse peritoneal mast cells in varying 
conditions. We wanted to study whether the activity of chymase would increase in 
same relation with the mast cell number and whether the natural inhibitors present in 
plasma and intraperitoneal fluid would affect chymase activity. 
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Figure 1. The effect of the MC granule releasing method on the chymase activity.  
Chymase activity as % in absence of serum is set as 100 % activity.  
Absolute chymase activity (AU) of the preparations in the absence of serum was 17 ± 
1.0,  38  ± 3.2 and 46  ± 3.6 for chymase in lysis buffer with 2 M NaCl, in lysis buffer 
without NaCl and for sonication in PBS, respectively. In all of the chymase activity 
measurements the results represented in figures are the means of triplicates ± SD. 
 
Before we could determine the effect of the natural inhibitors in IP fluid, we had to 
see, whether the collecting method of IP fluid would effect the results. Intraperitoneal 
fluid had a partial inhibitory effect on chymase when the cells from the peritoneal 
fluid were removed (Figure 2). Initially, we used raw intraperitoneal fluid containing 
peritoneal cells. This preparation displays chymase activity, apparently increasing the 
activity of chymase. This is due to the collecting method of IP fluid where the 
peritoneal MCs were taken along with the peritoneal fluid. It would appear that 
intraperitoneal fluid would increase the activity of chymase but when the MCs were 
removed from the IP fluid preparation, activity decreased as higher was the IP fluid 
concentrations, and the activity remained in the sediment. Three preparations of 
intraperitoneal fluid were used: (a) no centrifugation, (b) low speed centrifugation of 
200 x g, 5 minutes, where the cells were removed and (c) high speed centrifugation of 
10 000 x g, 10 minutes, where also the MC granules were removed. The chymase 
activity was not markedly decreased in the reaction mixture containing high speed 
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centrifuged IP fluid compared to the low speed centrifugation, thus the activity was 
mainly caused by the MCs in the intraperitoneal fluid and not by granules released by 
the MCs. In the following experiments we chose to use the low speed centrifugation. 
 
 
Figure 2.  The effect of the 
preparation type of 
intraperitoneal fluid on chymase 
activity  
Chymase activity in intraperitoneal 
fluid, three preparations. High 
chymase activity in the sediment and 
in preparation containing cells from 
the peritoneal cavity. Results are 
expressed as means ± SD. 
 
 
 
 
Mast cell lysastes obtained by sonication showed a linear relation between mast cell 
numbers and chymase activity up to at least 50 000MCs per assay (Figure 3A). To 
evaluate the inhibitory effect of the natural inhibitors on chymase, chymase activity 
was determined in the presence of increasing concentrations of serum and IP fluid 
ranging from 0% to 80%. There was a marked decrease in chymase activity in 
increasing plasma concentrations. 
Serum has high concentration of protease inhibitors and thus exerted a strong 
inhibitory effect on chymase activity (Figure 3B).  At a serum concentration of 10%, 
chymase has lost more than 50% of its activity. At a serum concentration of 50% 
almost all of activity is lost and at 80% serum concentration all of the activity is lost. 
In contrast, chymase in the IP fluid preparations remained partially active although it 
lost almost half of its activity at 10% of IP fluid concentration. Importantly at 80% 
peritoneal fluid concentration more than 40% of chymase is still active. These 
findings revealed that the mouse peritoneal cavity was a suitable compartment for 
further studies of the physiological consequences of mast cell activation in vivo and 
 20 
also suggested that chymase-dependent HDL proteolysis could also occur in other 
extra vascular compartments. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Chymase activity in a mouse mast cell lysate in the presence of mouse 
serum and intraperitoneal fluid 
(A) Chymase activity in a peritoneal mast cell lysate obtained by sonication and 
expressed as a function of mast cell number. (B) Chymase activity of the lysate (20 
000 mast cells in the assay) was evaluated in the presence of increasing 
concentrations of mouse serum and intraperitoneal fluid. (% in PBS and expressed as 
a percentage of the total activity (in the absence of inhibitors). Results are means of 
triplicates ± SD 
 
 
4.2. Proteolytic inactivation of human apoA-1 by mouse chymase 
Next we wanted to asses whether the mouse chymase would proteolytically inactivate 
human apoA-1 like its human and rat counterparts do [27]. ApoA-1 was treated with 
increasing amounts of mouse mast cell lysate at 37°C for 3 h in water bath and after 
the incubation apoA-1  proteins were detected in SDS-PAGE by Western Blotting. 
Degradation of apoA-1 could already be seen with the lowest chymase activity (18U) 
(Figure 4A, top). Chymase treatment led to full loss of intact apoA-1 band and 
generated a major proteolytic fragment of 26 kDa. Treatment with chymase also led to 
almost complete inhibition of the ability of apoA-1 to promote cholesterol efflux from 
cultured mouse macrophage foam cells (Figure 4A, bottom). 
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Our next aim was to test whether apoA-1 injected to the peritoneal cavity of a mouse 
would be degraded when peritoneal mast cells were locally activated with mast cell 
activating compound C48/80. Mice were injected with two separate intraperitoneal 
injections, apoA-I and C48/80 0,5-1 mg/kg. After 3 hours, serum and peritoneal fluid 
were collected and their ability to promote cholesterol efflux from cultured mouse 
foam cells was evaluated. We found that there was a C48/80 dose dependent decrease 
in efflux-inducing activity of intraperitoneal fluid when 30mg/kg of apoA-1 was 
injected. To be noted, the lowest amount (3mg/kg) of apoA-1 injected 
intraperitoneally was able to increase the cholesterol efflux promoted by 
intraperitoneal fluid by two fold, local activation was able in such mice however, to 
fully block the stimulatory effect of apoA-1 (Figure 4B) 
 
Figure 4.  Mast cell dependent proteolytic 
inactivation of human apoA-1 induced in 
vitro and in vivo 
Human apoA-1 was incubated with increasing 
concentrations of mouse MC lysate (chymase 
activity 20U/µl) in a final volume of 250µl in 
TNE buffer. After 3 h incubation samples were 
applied to 15% SDS-PAGE and apoA-1 was 
detected by Western blotting (top), or they were 
added to cultured [3H]CE-labelled mouse 
peritoneal macrophage foam cells (bottom). 
After 4 h incubation, efflux of cholesterol was 
determined and expressed as dpmmedium/(dpmcells 
+ dpmmedium) x 100. (B) To stimulate local 
degranulation of peritoneal MCs, mice were 
given i.p. injections of C48/80 together with 
apoA-1.Two control groups received either only 
apoA-1 or only PBS. Cholesterol efflux was 
then determined as described above. Values are 
means of triplicates ± SD. 
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4.3  Efflux of cholesterol from macrophage foam cells promoted by mouse serum 
and intraperitoneal fluid in the three activation models 
The results from the in vivo experiments showed that the chronic and sub acute 
stimulation cause only a very modest effect on the cholesterol efflux ability of serum. 
In the chronic stimulation cholesterol efflux promoted by mouse serum was not 
decreased in the stimulated mice compared to the control mice. In the sub acute 
stimulation cholesterol efflux was decreased but the reduction was not statistically 
significant (results not shown). Clear results were only observed in the acute 
stimulation where mice were given a high dose 8mg/kg of C48/80 that causes 
anaphylactic shock, thus leading to systemic activation of mouse mast cells. In the 
acute stimulation cholesterol efflux promoted by mouse serum and IP fluid from 
cultured mouse macrophage foam cell was clearly decreased in the stimulated mice 
compared to the control mice (Figure 5A and B). Efflux was decreased since 
cholesterol acceptors in serum and IP fluid have been degraded by proteases released 
by MCs, namely chymase (not shown).  As a control for this experiment we 
performed the same protocol on mast cell deficient W-sash c-kit mutant mice. The 
mice were injected the same 8mg/kg of C48/80 and the animals were sacrificed 30 
minutes after injection. Efflux promoted by serum and intraperitoneal fluid from the 
stimulated and the control mice were essentially the same (5C and D). There was no 
decrease in the ability of cholesterol acceptors to promote cholesterol efflux in the 
stimulated mast cell deficient mice thus providing conclusive evidence that the 
inhibitory effect seen in NMRI was indeed caused by the acute mast cell response.  
 
Cholesterol concentrations from the serum of stimulated and control mice in the three 
methods of activating mast cells in vivo were determined to explain the possible effect 
of differences in the amount of lipoprotein acceptors in the efflux of cholesterol from 
macrophages to serum.  
MC stimulation does not only lead to release of chymase but also in the release of 
other proteases and inflammatory mediators. Histamine is one of these mediators and 
one of the main factors causing the harmful effects of anaphylactic shock. Apart from 
its other actions, histamine causes dilatation and increased permeability of venules. 
This could lead to a decreased serum concentration of cholesterol acceptors.  Yet it 
can be seen that in the in vivo experiment the cholesterol in serum is not much  
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Figure 5 Cholesterol efflux from macrophage foam cells promoted by serum and 
intraperitoneal fluid.  
(A and B) Female NMRI mice N=10 received an injection of  C48/80 (8mg/kg of 
body weight). Control mice N=10 received an equal amount of PBS. (C and D) Mast 
cell deficient sash mice (6 animals/group) received equal amounts of C48/80 and 
PBS. The ability of mouse serum and intraperitoneal fluid to promote cholesterol 
efflux was determined in both experiments.  Measurements were done in triplicates 
and results shown in figure are the means of the three measurements ± SD 
 
 
different in the stimulated than in the control mice. In the acute stimulation the serum 
concentration is the same in the stimulated and control mice, in the sub acute 
stimulation the concentration is lower in the stimulated mice and in the chronic 
stimulation cholesterol concentration is a little higher. These results reveal that there 
was no remarkable change in the concentration of cholesterol acceptors in plasma of 
stimulated mice. (Table 1).  
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MCs were obtained from the IP cavities of stimulated mice and chymase activity was 
measured from a pooled sample of a test group of ten mice (Table 1) and expressed as 
average of triplicates. The activity of chymase in the MCs of the acutely stimulated 
mice is significantly lower in the stimulated than in the control mice. This does not 
however apply to the sub acutely stimulated mice. The chymase activity in these MCs 
appears to be higher in the stimulated than in the control mice. In the chronic 
stimulation the activity of the peritoneal MC chymase is again lower than in the 
stimulated. It can be presumed that peritoneal MC would have released their chymase 
to their environment and that the chymase activity would be lower in the MC 
preparate from the stimulated mice. MCs are able to take back some of the chymase 
they have released to their environment but this is unlikely to explain the results from 
stimulated and control mice in the sub acute and chronic stimulation. Also the 
chymase activities between the control groups of each test group vary greatly. The 
reason for this confusing fact is unknown. The test groups were chosen so that the 
mice would match within the test group but the experiments were performed on 
separate times and the mice were for this reason from different litters and also not 
exactly of the same age. This does not however explain the difference.  
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Table 1. 
 
 Chymase activity,  
average of all MC 
samples (AU) 
Cholesterol in plasma, 
average of all test group 
(mmol/l) 
stimulated control stimulated control 
Acute 
stimulation 
5.6  17.3  1.66 ± 0.65 
 
1.86 ± 
0.71 
 
Sub acute 
stimulation 
57.3  41.3  2.51 ± 0.47 
 
3.49 ± 
0.82 
 
Chronic 
stimulation 
11.7  43.0 2.51 ± 0.31 
 
2.33 ± 
0.4 
 
 
Table 1. Chymase activity from peritoneal MCs pools of stimulated and control 
mice and cholesterol concentration in serum.  
Activation of mast cells did not affect the cholesterol composition of mouse 
plasma between stimulated and control group. Activity of chymase is 
decreased in acute and chronic stimulation since MC proteases have been 
released to the environment. Why this does not occur in sub acute stimulation 
is unclear. Results for chymase are means of triplicates and results for 
cholesterol are the averages of individual serum samples measured in 
duplicate.   
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5. Discussion.  
 
It has been previously demonstrated that inactivation of lipid-poor species of HDL in 
vitro results in a decreased ability of HDL3 and plasma to promote ABCA1-dependent 
efflux from macrophage foam cells [28]. To be able to use the mouse as our model in 
vivo we had to determine the characteristics of mouse mast cell chymase like protease 
mMCP-4 which is the mouse counterpart of human chymase. There is also an other 
mouse mast cell protease (mMCP-1) present in the mucosal surfaces of the mouse, but 
this protease quickly makes complexes with other proteins and becomes inactivated 
once released in plasma [29]. MMCs were obtained from peritoneal cavities of adult 
NMRI mice and mMCP-4 obtained by sonication of the cells. Chymase activity was 
measured in the presence of natural inhibitory of chymase found in plasma and IP 
fluid. Serum had a very strong inhibitory effect on mMCP-4 but in the IP fluid 
mMCP-4 was able to maintain partially its enzymatic activity. This is likely due to its 
release bound with heparin proteoglycans which to some extent protect it from the 
inhibitors present in body fluids. These findings are in line with previous studies in 
vitro that have shown that the bound chymase can remain active even when it is 
surrounded by its natural inhibitors [30].  
In the presence of IP fluid chymase was able to sustain its activity even in high IP 
fluid concentrations. This result is important for our future studies which aim to 
expand the mouse studies to a model that evaluates the rate of RCT from 
macrophages located in the peritoneal cavity when peritoneal mast cells are activated.  
 
The systemic activation of mast cell efficiently led to the release of mast cell granules 
and our model allowed us to evaluate the effect of mast cell activation on the 
cholesterol efflux-promoting ability of HDL. Our results demonstrate that mouse 
plasma and IP fluid were defective in promoting cholesterol efflux from cultured 
macrophage foam cells and that the impaired effect was due to mast cell activation 
and MC-dependent degradation of HDL particles, thus generating to dysfunctional 
HDL in vivo. 
 
In our present study we report a MC chymase-dependent inactivation on the 
cholesterol acceptor ability of the HDL particles in vivo. The cholesterol removal 
from atherosclerotic arteries in the course of the disease is not only dependent on the 
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number of HDL particles present in the intima but on also their activity. Since the 
small subpopulations (apoA-I, apoE, apoA-IV) of HDL are highly susceptible to 
chymase-mediated proteolysis, the proteolytic inactivation of these particles could be 
a pro-atherogenic risk factor. The decreased ability of cholesterol acceptors to 
promote cholesterol efflux impairs the first step of reverse cholesterol transport. The 
activation of chymase indeed can cause a declined RCT and thus chymase inhibitors 
may in the future be an important part in the preventition of cardiovascular disorders. 
 
The results of this study indicate that mast cell activation may have a deleterious 
effect at least in the first step of reverse cholesterol transport. In our study we 
activated the mast cell artificially with IP injections of mast cell degranulating 
compound 48/80. It will be interesting to see, whether physiological stress caused by 
other conditions associated to activation of MCs in vivo would lead to same kind of 
results as indicated in this study. Our study has given some valuable information for 
constructing new methods for studying atherosclerosis but our present model is based 
on local mast cell degranulation in the peritoneal cavity and on systemic mast cell 
degranulation in all tissues, and thus to obtain more specific information in detail 
about pathogenesis of the disease, further studies in which arterial mast cell are 
locally stimulated in arterial wall of mice must be carried out.  
 
 
Further analysis of the samples involved in this study was carried out and clear 
qualitative and quantitative changes in the apoA-I were observed. The results of the 
analysis and the ones documented were published in 2009.  
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Study limitations 
The limits that animal models involve include the variability between individual mice 
and the difficulty of standardizing the experiment conditions. We saw in our 
experiment that there was an unexpected variation e.g. in responses to treatments 
between individual mice even though they came from the same litter and were of the 
same sex. The variables can be attempted to be minimized by using a larger number 
of laboratory animals and always using the same person handling the laboratory 
animals.  
When results from mouse studies are adapted to analogous human conditions certain 
limitations must be considered. Mouse is very resistant atherosclerosis and lipoprotein 
profiles of human and mouse differ. Other physiological differences such as the great 
diversity of mast cell proteases among the various animal species used as a surrogate 
model to study human disease impose limitations to these studies.  
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